comparemela.com

Latest Breaking News On - University of birmingham enterprise - Page 22 : comparemela.com

Agents that target viral RNA could be the basis for next generation anti-viral drugs

 E-Mail A new approach to tackling viruses by targeting the control centre in viral RNA could lead to broad spectrum anti-viral drugs and provide a first line of defence against future pandemics, according to new research at the University of Birmingham. In a new study, published in Angewandte Chemie, researchers have shown how this approach could be effective against the SARS-CoV-2 virus responsible for the COVID-19 pandemic. Earlier modelling and in vitro analysis by the team and published in Chemical Science has also shown effectiveness against the HIV virus. Professor Mike Hannon, from the University of Birmingham s School of Chemistry, is co-lead author of the study. He said: Although SARS-CoV-2 vaccines have been developed with unprecedented speed, there has still been a 12-month wait for development and approval. Viral pandemics remain a big threat and so broad-spectrum anti-virals are urgently needed to keep diseases like coronaviruses at bay while effective dru

Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science

Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb DGAP-News: Evotec SE / Key word(s): Miscellaneous 06.05.2021 / 07:30 beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR Hamburg, Germany, 06 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from

UK s Linear Diagnostics secures £800k for point of care diagnostics platform

UK s Linear Diagnostics secures £800k for point of care diagnostics platform UK s Linear Diagnostics secures £800k for point of care diagnostics platform 24 February 2021 | News The funds received by the University of Birmingham spinout will enable Linear Diagnostics to develop a prototype single-use cartridge and reader for our duplex test for chlamydia and gonorrhoea Photo Credit: Freepik Birmingham-based Linear Diagnostics Ltd has secured £800,000 from the Midlands Engine Investment Fund (MEIF) and other investors in the company’s second round of funding, which will enable the company to commence the development of the hardware platform for its tests . The finance will facilitate the ongoing development of the company’s high-speed platform technology for point-of-care diagnostics. The funding package includes backing from MEIF Equity Finance, managed by venture capital firm Midven, the University of Birmingham and the UKI2S Fund. The UK Futu

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.